Nasus Pharma (NSRX) Income Statement (2023 - 2025)
Annual Income Statement report data from Dec 31, 2023 to Dec 31, 2025 for Nasus Pharma (NSRX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| 2025 | 2024 | 2023 | |
|---|---|---|---|
Revenue and COGS | |||
Total Revenue | 1.24B | - | - |
Operating Expenses | |||
Research And Development | 2.24M (+558.82%) | 340K (-40.35%) | 570K |
Selling General And Administrative | 2.67M (+260.81%) | 740K (+27.59%) | 580K |
Operating Expenses | 4.90M (+353.70%) | 1.08M (-6.09%) | 1.15M |
Operating Income | |||
Operating Income | -4.90M (+353.70%) | -1.08M (-6.09%) | -1.15M |
Ebit | -4.90M (+353.70%) | -1.08M (-6.09%) | -1.15M |
EBITDA | -5.93M (+295.33%) | -1.50M (+50.00%) | -1.00M |
Other Income / Expenses | |||
Interest Expense | -80.00K | 30K (-40.00%) | 50K |
Net Income | |||
Net Income From Continuing Operations | -5.86M (+283.01%) | -1.53M (+45.71%) | -1.05M |
Net Income | -5.86M (+283.01%) | -1.53M (+45.71%) | -1.05M |